Pharmacology in the Catheterization Laboratory 1st Edition by Ron Waksman, Andrew Ajani ISBN 1405157046 9781405157049
Original price was: $50.00.$35.00Current price is: $35.00.
Pharmacology in the Catheterization Laboratory 1st Edition by Ron Waksman, Andrew Ajani – Ebook PDF Instant Download/Delivery: 1405157046, 9781405157049
Full download Pharmacology in the Catheterization Laboratory 1st Edition after payment
Product details:
ISBN 10: 1405157046
ISBN 13: 9781405157049
Author: Ron Waksman, Andrew Ajani
Cardiologists today prescribe medications with complex mechanisms of action, pharmacokinetics, indications, contraindications and drug-frug interactions; many of which were not available when today’s practitioners were in training. This book was written to meet the growing demand for complete, detailed and accurate cardiac pharmacology information.
This in-depth examination of the specific types of pharmacological agents used in the cardiac catheterization lab – as well as those routinely prescribed for cardiac patients – evaluates drugs with respect to their:
- Cellular and physiological actions
- Prescribed usage
- Dosages
- Adverse reactions
- Cautions
- Common routes of administration
Opening chapters discuss anticoagulation therapies and antiplatelet therapies. later chapters cover percutaneous coronary intervention and its possible complications, post-procedure pharmacotherapy, and anticoagulation anomalies.
Drawing on the expertise of contributors from around the world, Pharmacology in the Catheterization Laboratory is the perfect blend of evidence and experience.
Table of contents:
Part I : Elective PCI Anticoagulation Therapy/Thrombin Inhibitors
CHAPTER 1 Optimal Antithrombotic Therapy
CHAPTER 2 Low Molecular Weight Heparin in the Catheterization Laboratory
CHAPTER 3 Direct Thrombin Inhibitor: Bivalirudin
CHAPTER 4 Fondaparinux in the Cardiac Catheterization Laboratory
Part II : Antiplatelet Therapy
CHAPTER 5 Optimal Antiplatelet Therapy: Duration of Antiplatelet Therapy with Drug-Eluting and Bare Metal Stents
CHAPTER 6 Clopidogrel: How Much, How Soon, and How Long
CHAPTER 7 Loading Strategies of Clopidogrel
CHAPTER 8 Cangrelor
CHAPTER 9 Prasugrel: A Novel P2Y12 Receptor Inhibitor
CHAPTER 10 When to Use Glycoprotein IIb/IIIa Inhibitors and Which One to Use: Abciximab, Tirofiban, or Eptifibatide?
Part III : Acute Coronary Syndrome STEMI/NSTEMI
CHAPTER 11 Antithrombotic Therapy for Non ST-Elevation Acute Coronary Syndromes
CHAPTER 12 Non Antithrombotic Postprocedural Pharmacotherapy: The Role of Statins, Beta-Blockers, Angiotensin-Converting Enzyme, or Aldosterone Inhibitors in Acute Coronary Syndromes and Elective Percutaneous Coronary Interventions
CHAPTER 13 Primary Percutaneous Coronary Intervention for ST Elevation Myocardial Infarction: Summary of Optimal Anticoagulation, Glycoprotein IIb/IIIa Platelet Inhibitors, and Other Antiplatelet Therapies
CHAPTER 14 Rescue Percutaneous Coronary Intervention
CHAPTER 15 Facilitated Primary Percutaneous Coronary in Acute ST-Elevation Myocardial Infarction
CHAPTER 16 Streptokinase, Alteplase, Reteplase, or Tenecteplase
CHAPTER 17 Intracoronary vs Intravenous Glycoprotein IIb/IIIa Inhibitor Use
CHAPTER 18 Upstream vs Procedural Use of Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes
CHAPTER 19 High-Dose Tirofiban
CHAPTER 20 Oral Anticoagulation Issues in Percutaneous Coronary Intervention
Part IV : Elective PCI Miscellaneous
CHAPTER 21 Agents to Optimize Access of Radial Artery Approach
Part V : High-Risk PCI
CHAPTER 22 Diabetes Mellitus
CHAPTER 23 Cardiogenic Shock
CHAPTER 24 High-Risk Coronary Intervention and Renal Dysfunction
CHAPTER 25 Renal-Protective Agents
CHAPTER 26 Radiocontrast-Induced Nephropathy
CHAPTER 27 Ideal Contrast Agent
Part VI : PCI Complications
CHAPTER 28 The No Reflow Phenomenon: Etiology, Prophylaxis, and Treatment
CHAPTER 29 Arrhythmia Management in the Cardiac Catheterization Laboratory
CHAPTER 30 Tachyarrhythmias Management
CHAPTER 31 Bradyarrhythmias Management (Intravenous Atropine, Adrenaline, Indications for Temporary Pacing Wire)
Part VII : Postprocedural Pharmacotherapy
CHAPTER 32 Management of Patients on Long-Term Anticoagulation
CHAPTER 33 Indication for Anticoagulation Post-Percutaneous Coronary Intervention
CHAPTER 34 Clopidogrel Use in Patients Requiring Coronary Artery Bypass Grafting
Part VIII : Anticoagulation Anomalies
CHAPTER 35 Heparin-Induced Thrombocytopenia
CHAPTER 36 Thrombocytopenia, Anemia, and Transfusion of Blood Products in Patients Undergoing Percutaneous Coronary Interventions
CHAPTER 37 Antiplatelet Therapy Resistance: Definition, Diagnosis, and Clinical Implications
CHAPTER 38 Reversal of Anticoagulation: Protamine
CHAPTER 39 Thrombocytopenia Post-Percutaneous Coronary Interventions: Glycoprotein IIb/IIIa-Induced
Part IX : Systemic Pharmacotherapy for in-Stent Restenosis
CHAPTER 40 Is Oral Rapamycin Plus Bare Metal Stents a Feasible Alternative to Drug-Eluting Stents? Lessons Learned from Argentina Observational and Randomized Studies (ORAR I, II, and III Trials)
CHAPTER 41 Systemic Paclitaxel for Prevention of Restenosis
CHAPTER 42 Systemic Pharmacotherapy for in-Stent Restenosis: Steroids
CHAPTER 43 Oral Agents to Prevent in-Stent Restenosis (Oral Sirolimus and Glitazones)
CHAPTER 44 Novel Pharmacotherapy in Percutaneous Coronary Intervention
People also search for:
cath lab pharmacology
catheterization lab procedures
catheterization laboratory technician
catheterization laboratory nurse
catheterization laboratory technologist
Tags: Ron Waksman, Andrew Ajani, Pharmacology, Catheterization Laboratory